With phosphodiesterase inhibitors (PDE-Is) showing significant promise in shortening tuberculosis treatment, we assessed the effect of roflumilast, an FDA-approved type 4 PDE-I, in both acute and chronic murine models of tuberculosis. Alone, roflumilast had no effect on lung bacillary burden and mortality. However, when roflumilast was used in combination with isoniazid, a reduction in lung bacillary burden was observed. These data suggest that roflumilast may be a good candidate for tuberculosis host-directed therapy (HDT).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649180 | PMC |
| http://dx.doi.org/10.1128/AAC.02145-15 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
D609 Suppresses Antituberculosis Response by Regulating Dendritic Cells Antigen Presentation.
Immun Inflamm Dis
December 2024
Department of Clinical Laboratory, Zhongshan Second People's Hospital, Zhongshan, Guangdong, China.
Objective: To elucidate the role of phosphatidylcholine-specific phospholipase C (PC-PLC) in the antituberculosis (anti-TB) immune response mediated by dendritic cells (DCs).
Methods: In vivo, C57BL/6J mice infected with the Mycobacterium tuberculosis strain H37Rv. Before infection, the mice were pretreated with the PC-PLC inhibitor D609.
Pharmacological inhibition of macrophage triglyceride biosynthesis pathways does not improve Mycobacterium tuberculosis control in infected mice.
J Infect Dis
November 2024
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Tuberculosis (TB) necrotic granulomas contain triglyceride-rich macrophages (foam cells) with reduced antimicrobial functions. We assessed the ability of two compounds to reduce triglyceride content and Mycobacterium tuberculosis (Mtb) burden in infected human monocyte-derived macrophages and in the lungs of Mtb-infected C3HeB/FeJ mice: A-922500 (DGATi), an inhibitor of diacylglycerol acyltransferase 1; and LY2584702 (p70S6Ki), an inhibitor of p70 S6 kinase. DGATi and p70S6Ki significantly reduced the lipid content and bacillary burden in Mtb-infected macrophages.
View Article and Find Full Text PDFImpact of an intranasal L-DBF vaccine on the gut microbiota in young and elderly mice.
Gut Microbes
November 2024
Bond Life Sciences Center, University of Missouri, Columbia, MO, USA.
Article Synopsis
- Bacillary dysentery, caused by Shigella spp., is a severe disease affecting low- and middle-income countries, especially impacting vulnerable groups like infants and the elderly through fecal-oral transmission.
- Researchers developed a promising vaccine, L-DBF, combining key proteins that showed broad protection in mouse models, particularly for high-risk groups.
- The study found that intranasal vaccination with L-DBF caused notable changes in the gut microbiota of young and elderly mice, suggesting vaccination can significantly influence gut health and the interaction between the immune system and gut bacteria.
Levofloxacin activity at increasing doses in a murine model of fluoroquinolone-susceptible and -resistant tuberculosis.
Antimicrob Agents Chemother
November 2024
Sorbonne Université, Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, Paris, France.
High-dose levofloxacin was explored in a clinical trial against multidrug-resistant tuberculosis and failed to show increased efficacy. In this study, we used a murine model to explore the efficacy of a dose increase in levofloxacin monotherapy beyond the maximum dose evaluated in humans. A total of 120 4-week-old female BALB/c mice were intravenously infected with 10 CFU of H37Rv wild-type (WT) or isogenic H37Rv mutants harboring GyrA A90V or D94G substitutions; the MICs were 0.
View Article and Find Full Text PDFClinical Features, Adverse Events and Treatment Outcomes of Multidrug/Rifampicin-resistant Tuberculosis in Children and Adolescents: An Eight-year Retrospective Cohort Study in Bandung, Indonesia.
Pediatr Infect Dis J
September 2024
Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Background: Data on childhood and adolescent multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB) in Indonesia are lacking. We aimed to assess clinical features, adverse events (AEs) and treatment outcomes of childhood and adolescent MDR/RR-TB.
Methods: A retrospective cohort study was performed in children and adolescents aged <18 years treated for MDR/RR-TB at Hasan Sadikin General Hospital in Bandung, Indonesia, between June 2016 and March 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!